Moderate alcohol consumption is generally tolerated, but excessive drinking can increase the risk of dizziness, hypotension, and reduced erectile response. For optimal effectiveness, limit alcohol intake around the time you plan to take the medication.
Caverta tablets are round, film-coated, and typically bear a distinct imprint indicating the dose strength (e.g., “C 50” for 50 mg and “C 100” for 100 mg). Inactive ingredients may include lactose, magnesium stearate, and microcrystalline cellulose. Regional packaging variations can occur.
Standard employment drug screens do not test for sildenafil. However, sport governing bodies may include PDE5 inhibitors on prohibited substance lists for certain disciplines; athletes should verify the specific anti-doping regulations applicable to their sport.
Men with well-controlled hypertension can often use sildenafil safely, but uncontrolled blood pressure (> 180/110 mmHg) is a relative contraindication. The prescribing clinician should evaluate cardiovascular status before initiating therapy.
Yes, provided you carry a valid prescription and the original packaging. Some countries may require a customs declaration for prescription medicines; check the destination’s import regulations in advance.
Both are PDE5 inhibitors, but tadalafil has a longer half-life (up to 36 hours) and may be taken daily at a low dose. Caverta (sildenafil) has a shorter duration of action, which can be advantageous for on-demand use. Choice depends on patient preference, response, and side-effect profile.
Common excipients in Caverta tablets include lactose, magnesium stearate, and silicon dioxide. Individuals with lactose intolerance or specific excipient allergies should discuss alternatives with their pharmacist.
A standard prescription bottle with a child-proof cap is sufficient. Keep the medication away from heat and humidity, and avoid storing it in bathrooms or car trunks.
Sildenafil’s patent expiry in the UK occurred in 2021, and several generic manufacturers now market the drug under its chemical name. Prices and availability may vary, but the therapeutic effect remains equivalent to the branded product.
Sildenafil does not produce physiological dependence. Psychological reliance can develop in some individuals who fear erectile difficulties without the medication; counseling and open communication with a partner or clinician can help manage such concerns.
Caverta is a prescription-only medication (POM) marketed in the United Kingdom for the treatment of erectile dysfunction (ED). Its sole active ingredient is sildenafil, a phosphodiesterase-type 5 (PDE5) inhibitor. Available as a swallowed pill, Caverta is supplied in strengths of 50 mg and 100 mg. The drug is regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and must be prescribed by a qualified healthcare professional.
Sildenafil belongs to the PDE5 inhibitor class. In men with erectile dysfunction, the natural sexual response triggers the release of nitric oxide in the corpus cavernosum. Nitric oxide stimulates the production of cyclic guanosine monophosphate (cGMP), which relaxes smooth muscle and allows increased blood flow into the penile tissue, producing an erection.
PDE5 is the enzyme that breaks down cGMP. By selectively inhibiting PDE5, sildenafil prolongs the action of cGMP, enhancing and sustaining penile blood flow when sexual stimulation occurs. The drug does not cause an erection on its own; sexual arousal is still required.
Key pharmacologic points:
Caverta is approved by the MHRA for the diagnosis and treatment of erectile dysfunction in adult men. The indication covers men who experience difficulty achieving or maintaining an erection sufficient for satisfactory sexual performance. The medication is intended for use on an as-needed basis rather than continuous daily therapy.
Sildenafil, the active component, is also approved under a different brand (Revatio) for pulmonary arterial hypertension (PAH). However, Caverta is not marketed for PAH in the UK; any use for that condition would be off-label and must be guided by a specialist.
Typical patients include:
Evidence-Based Off-Label Uses
Pulmonary arterial hypertension (PAH): Sildenafil improves exercise capacity and hemodynamics in PAH patients. This use is formally approved for the Revatio formulation, not for Caverta. Off-label prescribing for PAH requires specialist supervision and is not covered by the Caverta product label.
Benign prostatic hyperplasia (BPH) symptom relief: Small studies suggest low-dose sildenafil may improve lower urinary tract symptoms, but evidence remains limited. Use for BPH is not approved and should only be considered within a clinical trial or specialist setting.
All off-label applications must be supervised by a qualified healthcare provider, with a thorough risk-benefit assessment.
Routine laboratory monitoring is not required for most men using Caverta. However, clinicians may consider:
Patients should contact their prescriber if they experience persistent visual loss, prolonged erection, severe chest pain, or any new cardiovascular symptoms.
This article provides educational information about Caverta and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
